Galenica Ag · SIX:GALE
Galenica — FY2024 Earnings Presentation
26 slides from Galenica's earnings presentation, Mar 11, 2025
Slide 1: Media and Analyst Conference
Media and Analyst Conference Zurich, 11 March 2025
Slide 2: Further pursuit of integrated healthcare
Further pursuit of integrated healthcare
Slide 3: Increased market share, improved profitability
Increased market share Improved profitability
Slide 4: Consultation plus established; clarity in home care; progress in digitalisation
«Consultation plus» established Clarity in the home care business Progress in digitalisation
Slide 5: Pharmaceutical Market Growth
+3.5% Pharmaceutical Market Growth © IQVIA – Swiss pharmaceutical market December 2024
Slide 6: Galenica Net Sales Growth
+4.7% Galenica Net Sales Growth
Slide 7: Consultations (+39%)
193,000 Consultations (+39%)
Slide 8: Net new locations (+2.7%)
10 Net new locations (+2.7%)
Slide 9: Omni-Channel to further gain importance
Omni-Channel to further gain importance
Slide 10: E-prescriptions redeemable in all Galenica pharmacies
E-prescriptions redeemable in all Galenica pharmacies
Slide 11: Verfora continued to grow and expand its market position
Verfora continued to grow and expand its market position
Slide 12: Home Care continues to be an area for growth
Home Care continues to be an area for growth
Slide 13: Wholesale Net sales growth
Wholesale +5.2% Net sales growth
Slide 14: Go-live of new ERP system in Lausanne-Ecublens
Go-live of new ERP system in Lausanne-Ecublens
Slide 15: Higher efficiency in transport services thanks to Health Supply
Higher efficiency in transport services thanks to Health Supply
Slide 16: Gross Margin
GGalenica 27.5% Gross Margin
Slide 17: Personnel costs in % of net sales
14.9% Personnel costs in % of net sales
Slide 18: Profit from continuing operations adjusted
+13.4% Profit from cont. operations adjusted1 1 Excluding the effects of IFRS 16 and IAS 19
Slide 19: Free Cash Flow
CHF 61 million Free Cash Flow1 1 Excluding the effects of IFRS 16 and IAS 19
Slide 20: Slight increase in market growth expected for 2025
Slight increase in market growth expected for 2025
Slide 21: Sales Guidance and EBIT Guidance
3-5% 4-6% Sales Guidance EBIT Guidance1 1 Excluding the effects of IFRS 16 and IAS 19
Slide 22: There for you every day. #StrongTogether
Values Added value in the network Shaping the future We generate value for customers We are shaping the healthcare and partners Vision of tomorrow Omni-Channel Digital Health Health Services & Products Connecting Healthcare Strategy Strategy Sustainably successful Pioneers in transition We work effi
Slide 23: Galenica
Galenica @i
Slide 24: Galenica Investor Day 2025
Galenica Investor Day 2025 Save the date: 28 October 2025
Slide 25: a SN
a \ a SN
Slide 26: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n